• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$41.11 -$0.05 (-0.12%)

REAL-TIME: Last trade at

Eli Lilly & Co.

NYSE:LLY

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 1

Eli Lilly announces Phase 3 study results for linagliptin

New Phase 3 data for Tradjenta® (linagliptin) tablets in black or African American patients with type 2 diabetes showed significant improvement in blood sugar

Lilly's GLP-1 Agonist Delivers

Lilly's GLP-1 Agonist Delivers - Analyst Blog

American College of Endocrinology (ACE) and Lilly Diabetes Offer New Tips to Help People With Diabetes Prepare for Emergencies

FTC, Senate probing blocking of generic drug companies, Washington Post says

Drotrecogin Alfa (Activated) in Adults with Septic Shock

Eli Lilly diabetes drug meets cardiovascular goals

Eli Lilly and Company's Diabetes Drug Meets Mid-stage Trial Goal

Eli Lilly announces positive data from Phase II study of GLP-1

Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting

Eli Lilly management to meet with Deutsche Bank

AstraZeneca looks to revive experimental drugs

Analysts' Actions: AZO, BMY, LLY, MS

Tough Market? Not for Defensive Stocks

Chicago Council on Global Affairs to host a symposium

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

Eli Lilly initiated with a Market Perform at BMO Capital

Cramer's 'Mad Money' Recap: A Fulcrum Moment

Cramer: The Book of LLY

For Carmel bicycle commuter, his way isn't the highway

Eli Lilly Could Sink On Drug Collusion In India

House Judiciary Committee to hold a hearing

Eli Lilly & Co Undervalued By Up To 30%

AstraZeneca among suitors eyeing Amylin

Summer Street's biotech research team hosts a luncheon meeting

Eli Lilly Is Ready To Soar On Strong Pipeline In 2013

Lilly Oncology To Disclose New Pipeline Data At ASCO 2012

Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer

4 Big Pharma Stocks To Nab In A Pullback

Cramer Answers Emails & 'Tweets'

Eli Lilly (LLY) Looks Like A Short

Eli Lilly and Company and Abbott Laboratories Win Big in Sales Rep Overtime Case

Eli Lilly wins OT pay case with sales rep

Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CYTR, GALE, EXEL, GNBT, GHDX, IMGN, NKTR, NLNK, PCYC, SGEN)

Novartis: A Deeply Undervalued Buy At $54

Two Miami Men Charged In $80 Million Drug Heist From Enfield Eli Lilly Warehouse